OSR Holdings (OSRH) Enters Binding Term Sheet for VXM01 License with BCM Europe; $815M Milestones, $30M Facility

OSR Holdings, Inc.

The binding term sheet grants BCM Europe exclusive worldwide rights to VXM01, with OSR Holdings providing up to $30M development financing to Vaximm AG.
BCM Europe Fund will pay up to $815M in milestone payments directly to OSR Holdings upon clinical and regulatory achievements.
OSR Holdings retains an equity option to issue up to $15M of common stock at $10/share (premium to market) to BCME Fund.
Royalties from an ultimate licensee will pass through to OSR Holdings after recovery of a negative milestone delta and minimum preferred return.
The transaction is a related-party deal requiring an independent fairness opinion; the term sheet supersedes a prior January 2026 term sheet.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.